

We Claim:

- 1 1. (Original) Amorphous rosuvastatin magnesium.
- 1 2. (Original) Amorphous rosuvastatin magnesium having purity greater than 99%
2 with diastereomeric impurity less than 0.5%.
- 1 3. (Original) Amorphous rosuvastatin magnesium according to claim 2 having purity
2 greater than 99.5% with diastereomeric impurity less than 0.25%.
- 1 4. (Original) Amorphous rosuvastatin magnesium according to claim 3 having purity
2 greater than 99.8% with diastereomeric impurity less than 0.15%.
- 1 5. (Original) Amorphous rosuvastatin magnesium substantially free of crystalline
2 rosuvastatin magnesium.
- 1 6. (Original) A process for the preparation of crystalline rosuvastatin magnesium
2 comprising:
 - 3 a) treating rosuvastatin methyl ammonium salt or rosuvastatin lactone with a
4 base and magnesium salt; and
 - 5 b) isolating crystalline rosuvastatin magnesium from the reaction mass.
- 1 7. (Cancelled)
- 1 8. (Cancelled)
- 1 9. (Original) A process for preparing amorphous rosuvastatin magnesium
2 comprising:
 - 3 a) dissolving crystalline rosuvastatin magnesium in a first organic solvent;
 - 4 b) adding a second organic solvent to the solution of rosuvastatin magnesium
5 or adding the solution of rosuvastatin magnesium to the second organic
6 solvent (in optional order of succession) wherein rosuvastatin magnesium is
7 insoluble or very slightly soluble or sparingly soluble in the second solvent,
8 such that amorphous rosuvastatin magnesium precipitates; and

9 c) isolating amorphous rosuvastatin magnesium.

1 10. (Original) A process for preparing amorphous rosuvastatin magnesium
2 comprising:

3 a) dissolving crystalline rosuvastatin magnesium in an organic solvent;

4 b) adding water to the solution of rosuvastatin magnesium, or adding the
5 solution of rosuvastatin magnesium to water (in optional order of
6 succession), such that rosuvastatin magnesium precipitates; and

7 c) isolating amorphous rosuvastatin magnesium.

1 11. (Cancelled)

1 12. (Original) A process for preparing amorphous rosuvastatin magnesium
2 comprising:

3 a) dissolving crystalline rosuvastatin magnesium in an organic solvent
4 optionally containing water; and

5 b) freeze drying or lyophilizing the solution to get amorphous rosuvastatin
6 magnesium.

1 13. (Cancelled)

1 14. (Cancelled)

1 15. (Cancelled)

1 16. (Original) A process for preparing rosuvastatin calcium comprising:

2 a) treating amorphous rosuvastatin magnesium with a base and a calcium salt;
3 and

4 b) isolating rosuvastatin calcium from the reaction mass.

1 17. (Cancelled)

- 1 18. (Original) Pharmaceutical composition to be used as HMG-CoA reductase
- 2 inhibitor in treatment of hyperlipidemia comprising amorphous rosuvastatin
- 3 magnesium.

- 1 19. (Original) A method for inhibiting HMG-CoA enzyme in treatment of
- 2 hyperlipidemia, comprising administering to a mammal in need thereof a
- 3 therapeutically effective amount of amorphous rosuvastatin magnesium.